ONCOMED PHARMACEUTICALS INC's ticker is OMED and the CUSIP is 68234X102. A total of 87 filers reported holding ONCOMED PHARMACEUTICALS INC in Q3 2015. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $9,220,000 | -24.8% | 1,195,897 | +11.5% | 0.00% | -33.3% |
| Q3 2016 | $12,255,000 | +18.6% | 1,072,171 | +27.7% | 0.00% | +50.0% |
| Q2 2016 | $10,333,000 | +24.1% | 839,388 | +1.9% | 0.00% | 0.0% |
| Q1 2016 | $8,325,000 | -54.1% | 823,398 | +2.4% | 0.00% | -50.0% |
| Q4 2015 | $18,122,000 | +24.8% | 803,980 | -8.1% | 0.00% | 0.0% |
| Q3 2015 | $14,517,000 | -22.0% | 875,028 | +5.8% | 0.00% | 0.0% |
| Q2 2015 | $18,617,000 | -0.7% | 827,409 | +13.8% | 0.00% | 0.0% |
| Q1 2015 | $18,752,000 | +21.8% | 727,381 | +2.8% | 0.00% | 0.0% |
| Q4 2014 | $15,397,000 | +22.2% | 707,591 | +6.3% | 0.00% | 0.0% |
| Q3 2014 | $12,604,000 | -18.2% | 665,846 | +0.7% | 0.00% | 0.0% |
| Q2 2014 | $15,400,000 | -6.8% | 660,957 | +34.6% | 0.00% | -20.0% |
| Q1 2014 | $16,527,000 | +24.6% | 491,139 | +9.3% | 0.01% | +25.0% |
| Q4 2013 | $13,261,000 | +560.4% | 449,216 | +242.5% | 0.00% | +300.0% |
| Q3 2013 | $2,008,000 | – | 131,168 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,042,989 | $8,571,000 | 0.75% |
| NEXTHERA CAPITAL LP | 634,715 | $1,346,000 | 0.26% |
| Endurant Capital Management LP | 219,114 | $465,000 | 0.21% |
| Birchview Capital, LP | 118,689 | $252,000 | 0.16% |
| Perceptive Advisors | 2,620,897 | $5,556,000 | 0.15% |
| Alambic Investment Management, L.P. | 53,972 | $114,000 | 0.09% |
| Sofinnova Investments, Inc. | 395,744 | $839,000 | 0.08% |
| Kazazian Asset Management, LLC | 31,475 | $67,000 | 0.06% |
| Broadfin Capital, LLC | 200,000 | $424,000 | 0.06% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 96,639 | $205,000 | 0.02% |